As indicated in Figure 6A, at the end (day 30) of the 4 week treatment cycle, the Ki-67 labeling index showed a reduced number of Ki-67-positive tumor cells in CPX –agent alone or combined with a gemcitabine treatment group in comparison to tumor cells from gemcitabine-treated animals, indicating the advantage of the CPX treatment over gemcitabine (Figure 6B). The gene discussed is MKI67; the disease is neoplasm.